NASDAQ:SNDX - Syndax Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $7.23 -0.04 (-0.55 %) (As of 10/19/2018 01:13 AM ET)Previous Close$7.27Today's Range$7.08 - $7.3252-Week Range$6.10 - $15.20Volume201,000 shsAverage Volume349,897 shsMarket Capitalization$188.71 millionP/E Ratio-2.48Dividend YieldN/ABeta1.27 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryInsider TradesHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company's lead product candidate is Entinostat, which is in Phase 3 clinical trial for the treatment of hormone receptor positive or HR+, human epidermal growth factor receptor 2 negative or HER2-, and breast cancer; and Phase 1b/2 clinical trial. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH, Genentech, Inc., Merck KGaA, Pfizer, and AstraZeneca; collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts. Receive SNDX News and Ratings via Email Sign-up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SNDX CUSIPN/A Webwww.syndax.com Phone781-419-1400 Debt Debt-to-Equity RatioN/A Current Ratio5.43 Quick Ratio5.43 Price-To-Earnings Trailing P/E Ratio-2.48 Forward P/E Ratio-2.32 P/E GrowthN/A Sales & Book Value Annual Sales$2.11 million Price / Sales80.01 Cash FlowN/A Price / CashN/A Book Value$4.28 per share Price / Book1.69 Profitability EPS (Most Recent Fiscal Year)($2.90) Net Income$-60,800,000.00 Net Margins-3,190.51% Return on Equity-80.35% Return on Assets-59.12% Miscellaneous Employees44 Outstanding Shares23,350,000Market Cap$188.71 million Syndax Pharmaceuticals (NASDAQ:SNDX) Frequently Asked Questions What is Syndax Pharmaceuticals' stock symbol? Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX." How were Syndax Pharmaceuticals' earnings last quarter? Syndax Pharmaceuticals Inc (NASDAQ:SNDX) released its quarterly earnings results on Tuesday, August, 7th. The company reported ($0.74) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.87) by $0.13. The company had revenue of $0.38 million for the quarter, compared to analysts' expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 80.35% and a negative net margin of 3,190.51%. View Syndax Pharmaceuticals' Earnings History. When is Syndax Pharmaceuticals' next earnings date? Syndax Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 6th 2018. View Earnings Estimates for Syndax Pharmaceuticals. What price target have analysts set for SNDX? 4 equities research analysts have issued 12 month price objectives for Syndax Pharmaceuticals' stock. Their forecasts range from $12.00 to $40.00. On average, they expect Syndax Pharmaceuticals' share price to reach $26.50 in the next year. This suggests a possible upside of 266.5% from the stock's current price. View Analyst Price Targets for Syndax Pharmaceuticals. What is the consensus analysts' recommendation for Syndax Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Syndax Pharmaceuticals. What are Wall Street analysts saying about Syndax Pharmaceuticals stock? Here are some recent quotes from research analysts about Syndax Pharmaceuticals stock: 1. According to Zacks Investment Research, "Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company's product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. " (10/10/2018) 2. HC Wainwright analysts commented, "Valuation: We base our $30 price target on probability-adjusted revenue forecasts for entinostat in combination with other drugs in advanced HR+, HER2- breast cancer, NSCLC, and metastatic melanoma. We use the net present value of our revenue forecast through 2027, apply a 35% POS for HR+, HER2- breast cancer, and 10% POS for NSCLC and melanoma, with a 3x price/sales multiple, and we value the early stage pipeline at $10 million, the amount of the upfront payments the company made to acquire the menin inhibitors and SNDX-6352, to arrive at our price target." (7/12/2018) Who are some of Syndax Pharmaceuticals' key competitors? Some companies that are related to Syndax Pharmaceuticals include Insys Therapeutics (INSY), ProQR Therapeutics (PRQR), Epizyme (EPZM), Flexion Therapeutics (FLXN), AMAG Pharmaceuticals (AMAG), Crinetics Pharmaceuticals (CRNX), ANI Pharmaceuticals (ANIP), Kura Oncology (KURA), Principia Biopharma (PRNB), Obseva (OBSV), CymaBay Therapeutics (CBAY), Urogen Pharma (URGN), Basilea Pharmaceutica (BPMUF), Vectura Group (VEGPF) and ChemoCentryx (CCXI). Who are Syndax Pharmaceuticals' key executives? Syndax Pharmaceuticals' management team includes the folowing people: Dr. Briggs W. Morrison, CEO & Director (Age 58)Mr. Michael A. Metzger, Pres & COO (Age 47)Mr. Richard P. Shea, CFO & Treasurer (Age 66)Dr. Michael L. Meyers, Chief Medical Officer & Sr. VP (Age 67)Dr. Peter Ordentlich, Co-Founder & Chief Scientific Officer (Age 49) When did Syndax Pharmaceuticals IPO? (SNDX) raised $66 million in an initial public offering on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup acted as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers. How do I buy shares of Syndax Pharmaceuticals? Shares of SNDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Syndax Pharmaceuticals' stock price today? One share of SNDX stock can currently be purchased for approximately $7.23. How big of a company is Syndax Pharmaceuticals? Syndax Pharmaceuticals has a market capitalization of $188.71 million and generates $2.11 million in revenue each year. The company earns $-60,800,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Syndax Pharmaceuticals employs 44 workers across the globe. What is Syndax Pharmaceuticals' official website? The official website for Syndax Pharmaceuticals is http://www.syndax.com. How can I contact Syndax Pharmaceuticals? Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The company can be reached via phone at 781-419-1400 or via email at [email protected] MarketBeat Community Rating for Syndax Pharmaceuticals (NASDAQ SNDX)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 183 (Vote Outperform)Underperform Votes: 194 (Vote Underperform)Total Votes: 377MarketBeat's community ratings are surveys of what our community members think about Syndax Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNDX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/19/2018 by MarketBeat.com StaffFeatured Article: What is the Book Value of a Share?